论文部分内容阅读
目的 观察以羟基喜树碱为主联合化疗治疗晚期消化系统恶性肿瘤的近期疗效。方法 含HCPT组:HCPT 10mg d_(1-5)ivgtt,DDP 40mg d_(1-3)ivgtt,5-Fu 500mg d_(1-5)ivgtt,MMC 10mgd_1iv;对照组:5-Fu 500mg d_(1-5),MMC 10mgd_1iv。连用三个周期后,进行疗效确认。结果 治疗组有效率达46％,高于对照组,统计学差异显著,而毒副作用无明显增加,患者能够耐受。结论 羟基喜树碱作为Topo Ⅰ抑制剂,在效果上与烷化剂有协同或相加的作用,与DDP联合应用,效果显著,同时,因其是细胞周期特异性药物,与细胞周期非特异性药物MMC联合,能够提高疗效。
Objective To observe the short-term efficacy of hydroxycamptothecin combined with chemotherapy in the treatment of advanced malignant tumors of the digestive system. Methods HCPT-containing group: HCPT 10mg d_(1-5)ivgtt, DDP 40mg d_(1-3)ivgtt, 5-Fu 500mg d_(1-5)ivgtt, MMC 10mgd_1iv; control group: 5-Fu 500mg d_(1 -5), MMC 10mgd_1iv. After three consecutive cycles, the efficacy was confirmed. Results The effective rate of the treatment group was 46%, which was higher than that of the control group. The statistical difference was significant, while the toxic and side effects did not increase significantly. The patient was able to tolerate it. Conclusion As a Topo I inhibitor, hydroxycamptothecin has synergistic or additive effects with alkylating agents, and has a significant effect when combined with DDP. At the same time, hydroxycamptothecin is a cell cycle-specific drug and nonspecific to the cell cycle. The combination of drugs MMC can improve the efficacy.